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Somatic mutations in non-Hodgkin’s lymphoma frequently activate EZH2, a protein methyltransferase
responsible for H3K27 trimethylation. In this issue ofChemistry and Biology, Bradley and coworkers describe
a new set of EZH2 inhibitors amenable to probing the targetable role of H3K27 trimethylation in lymphoma.The human genome provides a common
text capable of encoding the hundreds
of different cell types found in the human
body. The malleable nature of genomic
information arises from the careful or-
chestration of gene expression. Higher
eukaryotes regulate gene expression by
housing genes within chromatin, the
nucleoprotein complex composed of his-
tones and DNA. Enzymes known as
chromatin modifiers add and remove
covalent modifications to histones that
correlate with changes in genomic acces-
sibility, providing a context that can either
permit or oppose transcription. Due to
their central role in gene expression, mu-
tation or dysregulation of chromatin mod-
ifiers can lead to the rapid rewiring of cell
function, facilitating transformation and
tumorigenesis.
One specific chromatinmodifier subject
to oncogenic mutation in many cancers is
the histone methyltransferase EZH2.
EZH2 is the catalytic domain of the poly-
comb repressive complex 2 (PRC2), an
evolutionarily conserved multiprotein as-
sembly responsible for keeping large
swathsof thegenome ina transcriptionally
‘‘off’’ state after differentiation (Di Croce
and Helin, 2013). Biochemically, EZH2 is
most proficient at catalyzing histone H3
lysine 27 (H3K27) monomethylation,
more slowly catalyzes dimethylation, and
only weakly promotes the trimethylated
state. However, in a wide variety of can-
cers—most notably non-Hodgkin’s lym-
phoma—EZH2 undergoes recurrent
gain-of-function mutations in its catalytic
domain that alter this substrate specificity,
allowing it to establish H3K27 trimethyla-
tion (H3K27me3) at a greatly increased
rate (Figure 1). By changing the substrate
specificity of EZH2, these mutations
harden a normally plastic epigenome,
constitutively silencing genes that would
ordinarily trigger senescence. This uniquegain-of-function mechanism has spurred
efforts to develop small molecule inhibi-
tors of mutant EZH2, which could pro-
vide powerful tools to understand PRC2
biology and assess the therapeutic poten-
tial of drugging the mutant gene.
In late 2012, groups fromGlaxoSmithK-
line, Epizyme, and Novartis published
concurrent reports on the discovery of
potent small molecule inhibitors of mutant
EZH2 (Knutson et al., 2012; McCabe
et al., 2012; Qi et al., 2012). Interestingly,
each of these inhibitors was based on
a 4,6-dimethyl 3-amidomethyl-pyridone
core. These molecules inhibited EZH2-
catalyed H3K27me3 in cells, promoted
transcriptional de-repression of select
genes, and displayed potent antiprolifera-
tive effects in cell and animal models of
EZH2 mutant lymphoma. In this issue of
Chemistry and Biology, Bradley et al.
(2014) build on their previous efforts
(Garapaty-Rao et al., 2013) and report
two new pyridone EZH2 inhibitors, CPI-
360 and CPI-169. A key early step in the
characterization of CPI-360 was the
finding that it inhibits mutant EZH2 50-
fold more potently than EZH1, another
PRC2-associated histone methyltransfer-
ase. This is nontrivial, because EZH1’s
catalytic domain is 96% identical to
EZH2. Interestingly, several studies have
suggested EZH1-associated PRC2 is
responsible for cellular H3K27 monome-
thylation, while EZH2-associated PRC2
is necessary for di- and trimethylation.
Identifying small molecules that selec-
tively inhibit EZH2 enables dissection of
the role these distinct modifications play
in disease phenotypes. Consistent with
studies of structurally related pyridones
(Knutson et al., 2012), CPI-360 sup-
pressed H3K27me2/me3 levels in lym-
phoma cells bearing an EZH2 mutation,
but did not inhibit H3K27me1. Together
with the selective biochemical inhibitionChemistry & Biology 21, November 20, 2014shown for EZH2 over EZH1, these find-
ings corroborate recent genetic data sug-
gesting that EZH2 controls H3K27me3,
while EZH1 may control bulk H3K27me1
levels (Hidalgo et al., 2012).
One common challenge in drug devel-
opment is determining that a biochemical
inhibitor actually engages its target in living
cells. Bradley et al. (2014) address this
issue using a label-free technology known
as a cellular thermal shift assay (CETSA)
(Martinez Molina et al., 2013). This method
allows them to not only verify interaction of
CPI-360/EZH2, but also to measure the
duration of CPI-360 occupancy following
drug removal. The verification of the small
molecule-EZH2 interaction at an early
stage provided a solid foundation from
which to launch mechanistic studies.
When compared with previously discov-
ered pyridones (Figure 1, bottom) CPI-
360 showed a similar ability to de-repress
EZH2-silenced gene expression, arguing
strongly for a conservedmechanismof ac-
tion. To augment these cellular studies,
Bradley et al. (2014) developed a structural
analog, CPI-169, with pharmacokinetic
properties amenable to animal studies.
This molecule induced regression of
EZH2 mutant tumor xenografts while
affecting H3K27me3, but not H3K27me1,
levels. Seeking to expand the applications
of thismolecule, theyalso tested itsactivity
against a panel of 43 lymphoma cell lines
comprising a range of EZH2 genotypes.
Surprisingly, these studies found the ef-
fects of EZH2 inhibitionwere not restricted
to EZH2 mutant lymphomas. This is not
completely unprecedented, as previous
studies of an EZH2 inhibitor GSK-126
had shown similar broad-spectrum anti-
lymphoma activity at elevated concentra-
tions (McCabe et al., 2012). In all cases,
phenotypic response was preceded by
potent suppression of H3K27me3,
implying an EZH2-mediated mechanism.ª2014 Elsevier Ltd All rights reserved 1419
Figure 1. Histone H3K27 Modification as a Central Hub for Oncogenic Signaling and
Therapeutic Intervention in Lymphoma
Activating (green) and inactivating (red) mutations in the histone lysine modification machinery drive the
equilibrium of H3K27 modification toward trimethylation, a state associated with transcriptional repres-
sion. Transcriptional repression can be relieved by targeting the methyltransferase activity of EZH2, a
member of polycomb repressive complex 2 (PRC2). Bottom: structurally-related 3-amidomethyl pyridone
inhibitors of EZH2. All three inhibitors inhibit EZH2-containing PRC2 selectively compared to EZH1-con-
taining complexes, resulting in specific effects on H3K27me2/3 in cells.
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type EZH2 may drive growth in these cell
lines, phenotypic responses did not corre-
late with H3K27me3 or EZH2 protein
levels, arguing against this simple interpre-
tation. Bradley et al. (2014) also showed in
some cell lines their EZH2 inhibitor syner-
gized with a selective inhibitor of BCL-2,
an antiapoptotic proteinwhoseexpression
is commonly amplified in non-Hodgkin’s
lymphoma. Exploiting such synergies
may provide a way to expand the reach
of EZH2-targeted therapies even further.
This latest chapter in the EZH2 inhibitor
story contains illustrative lessons for chro-
matinchemicalbiology.Forexample,while
EZH2 mutant lymphomas remain the best
starting point for clinical applications of
EZH2 inhibitors, the finding that the thera-
peutic effects of these molecules outstrip
their initially definedgeneticcontextmakes
the case that chemical probes for chro-
matin modifiers are likely to have unantici-
pated applications in disease research.1420 Chemistry & Biology 21, November 20,This is because, despite much work, our
knowledge of how different signaling cas-
cades propagate through chromatin re-
mains far from perfect. Chromatin modi-
fiers may represent critical dependencies
for signal transduction, regardlessofmuta-
tional status. For example, loss-of-function
mutations in the SWI/SNF chromatin re-
modeling complex cause malignant rhab-
doid tumors tobecome reliant onEZH2ac-
tivity for growth (Knutson et al., 2013).
Small molecules such as CPI-169 provide
powerful tools for defining these depen-
dencies and assessing their targetable
role in therapy.
Synergy studies such as those explored
by Bradley et al. (2014) likely represent a
major focus of future cancer research.
Just as cancer requiresmultiple cooperat-
ing mutations to cross the proliferation
threshold, multiple fronts of attack may
be necessary to stably repress oncogenic
phenotypes. Interestingly, in addition to
EZH2 mutations, many diffuse large B2014 ª2014 Elsevier Ltd All rights reservedcell lymphoma (DLBCL) patient samples
demonstrate loss-of-function mutations
in the chromatin modifiers EP300, CBP,
and UTX, all of which are involved in the
modification of H3K27 (Shaknovich and
Melnick, 2011). EP300/CBP are H3K27
acetyltransferases whose loss would
potentially clear the road for H3K27me3
establishment by mutant PRC2. UTX
encodes a demethylase that normally
removesH3K27me3 and is found in a sub-
setofDLBCLcells known tobesensitive to
EZH2 inhibition. Defining how cooperating
epi-mutations impact the efficacy of EZH2
inhibitorsmay helpmaximize the effects of
these agents. The flipside of this is that
EZH2 inhibitors also have the potential to
cooperate with existing biology to exert
deleterious phenotypes. For example,
loss of SUZ12, a noncatalytic member of
the PRC complex, appears to cooperate
withRas-activatingNF1mutations to facil-
itate growth in familial cancers, glioblas-
tomas, neuroblastomas, and lung cancers
(De Raedt et al., 2014). Thus, it has been
proposed that screening patients for NF1
mutations prior to administering EZH2 in-
hibitors may be a sensible step to avoid
activating latent protumorigenic NF1 mu-
tations. Understanding the balance of
positive and negative synergies will be
important to future applications of epige-
netic-targeted therapies.
One final question arising from these
studies is how precisely EZH2 inhibitors
exert their effects on gene expression.
Changes in histone modifications are
associated with altered gene expression,
but evidence for the direct causative na-
ture of these changes can be difficult to
come by. In line with this, expression
profiling has so far been unable to identify
a common set of genes activated by
EZH2 inhibitors that underlie their antipro-
liferative effects (McCabe et al., 2012).
This may be partially explained by the
recent proposal that PRC2 is required for
the maintenance, rather than the initiation,
of transcriptionally repressive chromatin
states (Riising et al., 2014). Notably, the
data of Bradley et al. (2014) indicate that
H3K27me3 removal and subsequent
gene activation require cell division,
consistent with EZH20s role in preserving,
rather than directly driving, transcriptional
repression (Bradley et al., 2014). While
the role of chromatin modifications as
‘‘cause’’ or ‘‘cog’’ in gene expression has
been hotly debated, both functions
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The ability of enzymes such as EZH2 to
reflect and amplify the underlying genomic
causes of disease suggests chromatin
modifierswill remain important therapeutic
targets for the foreseeable future.REFERENCES
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The evolutionary pathway of specialized metabolism often takes unexpected, perplexing turns. In this issue
of Chemistry & Biology, Feng and coworkers provide evidence for a unique phosphatase whose enzymatic
product plays a critical role in biofilm formation in Bacillus subtilis.Microbial biofilms have intrigued the
scientific community for centuries. Their
peculiarities have been influential in
prompting some of the earliest micro-
scopic studies as well as the more
modern, cutting edge molecular analyses
(Høiby, 2014). Although not given full
appreciation until the late 20th century,
biofilms have forged an expanding scien-
tific frontier that spans disciplines ranging
from healthcare to agriculture (Lappin-
Scott et al., 2014). Their effects, good
and bad, have continued to draw atten-
tion from researchers in many fields who
hope to identify and/or exploit interesting
and unique aspects of this ‘‘slimy’’ part
of the microbial world.
Despite the consensus that most mi-
crobes generate biofilms at some point
during their lifecycle, considerable varia-
tions exist in the mechanisms through
which biofilm formation is supported,
even among the most extensively studied
bacterial systems (Lo´pez et al., 2010).One of these systems, the Gram-positive
bacterium Bacillus subtilis, utilizes a com-
mon biofilm theme whereby a polysac-
charide matrix infused with proteins an-
chors cells to one another and a surface
(Vlamakis et al., 2013). While this and
other areas of biofilm formation tend to
follow common trends, other aspects of
the process seem to be species specific,
such as the signaling molecules that elicit
the biofilm response (Lo´pez et al., 2010).
In this issue of Chemistry & Biology,
Feng et al. (2014) add a very interesting
new layer to the requirements for biofilm
assembly in B. subtilis. These authors
provide evidence that not only does the
B. subtilis squalene synthase-like enzyme
(YisP) catalyze the formation of farnesol
(FOH) from farnesyl diphosphate (FPP),
but also that its product plays an impor-
tant role in biofilm assembly. Earlier work
by Lo´pez and Kolter (2010) originally pro-
posed YisP to be a squalene synthase
without truly identifying its reactionproduct. Additionally, Lo´pez and Kolter
(2010) demonstrated that when YisP was
knocked out in B. subtilis, the ability to
assemble biofilm was lost and therefore
surmised that squalene played an impor-
tant role in B. subtilis biofilm formation.
However, close inspection of the protein
sequence by Hu et al. (2013) during the
elucidation of the crystal structure for
YisP revealed that one of the canonical
aspartate-rich motifs found in all squalene
synthases was out of register in YisP.
Thus, with the YisP crystal structures
in hand (additional YisP structures were
solved for this work) and the discrepancy
found by Hu et al. (2013) in mind, the cur-
rent authors calculated the volume of the
YisP active site pocket and compared
it to the active site pocket volume of
the Staphylococcus aureus dehydrosqua-
lene synthase (CrtM) and human squalene
synthase (HsSS) enzymes. In comparing
these measurements, Feng et al. (2014)
realized that the YisP active site was likelyª2014 Elsevier Ltd All rights reserved 1421
